AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 04/17/23

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 22nd Annual Needham Virtual Healthcare Conference held on April 19, 2023. Mr. ...

2023-04-17 06:41:26 ET Amneal Pharmaceuticals ( NYSE: AMRX ) reports Q1 preliminary net revenue of $550 million to $560 million up 12% Y/Y against $529.36M consensus. Q1 loss before income taxes of $10M to $0, an improvement of ~50% Y/T. Adjusted EBITDA of $115M to $1...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced certain unaudited preliminary financial results for the first quarter ended March 31, 2023. The Company is also affirming financial guidance for the year ending December 31, 2023, which w...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2023 financial results on Friday May 5, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on May 5, ...

Amneal Pharmaceuticals, Inc. (AMRX) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET Company Participants Anthony DiMeo - Senior Director of Investor Relations Chirag Patel - President and Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer ...

Gainers: OncoSec Medical ( ONCS ) +44% . BioRestorative Therapies BRTX +32% . Astria Therapeutics ( ATXS ) +13% . Certara ( CERT ) +12% . Kazia Therapeutics ( KZIA ) +11% . Losers: ZimVie ( ZIMV ) -45% . Cano Health ( CAN...

The U.S. Food and Drug Administration (FDA) accepted for review Amneal Pharmaceuticals ( NYSE: AMRX ) application seeking approval of a generic version of opioid overdose therapy Narcan. Amneal had filed Abbreviated New Drug Application (ANDA) for naloxone hydrochl...

Amneal Pharmaceuticals press release ( NYSE: AMRX ): Q4 Non-GAAP EPS of $0.23 beats by $0.02 . Revenue of $610M (+13.6% Y/Y) beats by $30.07M . FY2023 Outlook : Net revenue of $2.25B to $2.35B vs. consensus of $2.31B and Adjusted diluted EPS of $0.40 to $0.50 vs. c...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Abbreviated New Drug Application (ANDA) for naloxone hydrochloride nasal spray, USP, 4mg, which is the generic version of Narcan ® and is used in the treatmen...

‒ Q4 2022 Net Revenue of $610 million; GAAP Net Loss of $4 million; Diluted Loss per Share of $0.03 ‒ ‒ Q4 2022 Adjusted Net Income of $71 million (1) , Adjusted EBITDA (1) of $154 million; Adjusted Diluted EPS (1) of $0.23 ‒ ‒ Full Y...